字号·· | 护眼
经济学人

长寿疗法将走出边缘地带Longevity treatments will move out from the fringe

点「原文对照」整页切到原文,或双击某段只看那段的原文。

人类延长寿命的路径,或许要经过人类最好的朋友。总部位于旧金山的初创公司Loyal正在研发延长老年犬寿命的药物。该公司预计在2027年获得美国监管机构批准,销售其主要候选药物——一种每日服用的药片,旨在模拟热量限制带来的部分延寿效果,同时不会导致体重下降或抑制食欲。对于希望活得更久的人类来说,来年可能也是重要的一年:长期以来专属于富人和怪人(有时两者是同一群人)的长寿疗法,正开始走向主流。

The path to a longer human life may run through man’s best friend. Loyal, a San Francisco-based startup, is developing drugs to extend the lifespan of older dogs. In 2027 the company expects to get approval from American regulators to sell its lead candidate, a daily pill designed to mimic some of the age-extending effects of calorie restriction without causing weight loss or suppressing appetite. The coming year could be an important one for humans hoping to live longer, too, as longevity treatments, long the preserve of the rich and the kooky (sometimes one and the same), start moving towards the mainstream.

长寿药物没有固定的定义。宽泛地说,它针对的是衰老的某种生物学成因,或有助于同时预防多种与年龄相关的疾病,从而延长“健康寿命”(一个人保持健康的年数)。美国药品监管机构食品药品监督管理局并不将衰老归类为疾病。因此,长寿药物必须针对特定的与年龄相关的病症进行测试,而不是针对衰老本身。

There is no fixed definition of a longevity drug. Broadly, it is one that targets a biological cause of ageing or helps prevent multiple age-related diseases at once, extending “healthspan” (the years a person spends in good health). The Food and Drug Administration, America’s drug regulator, does not classify ageing as a disease. Longevity drugs must therefore be tested against specific age-related conditions, not ageing in general.

在某些情况下,这些药物是已经存在的药物。用于治疗糖尿病和肥胖症的GLP-1药物可调节血糖和胰岛素。但研究人员发现,它们还能帮助患有心脏病、睡眠呼吸暂停以及肾脏和肝脏问题的患者。由于这些病症中有许多会随着年龄增长而变得更加常见,并导致过早死亡,一些研究人员已将GLP-1药物视为长寿药物。

In some cases these are drugs that already exist. GLP-1 medicines, used to treat diabetes and obesity, regulate blood sugar and insulin. But researchers have found that they can also help patients with heart disease, sleep apnoea, and kidney and liver problems. Because many of these conditions become more common with age and contribute to early death, some researchers already regard GLP-1s as longevity drugs.

近期研究更直接地证明了这一点。2026年5月,研究人员在《自然·通讯》上报告了一项试验的事后分析。该试验中,感染HIV并患有脂肪增生症(一种腹部周围脂肪过度堆积的病症)的人服用了司美格鲁肽(丹麦诺和诺德公司以Ozempic品牌销售)。约七个月后,服药者显示出生物学衰老放缓的迹象,这是通过“表观遗传时钟”测得的,该检测估算的是生物学年龄而非实际年龄。这种药物似乎通过减少持续性炎症起作用,而炎症会加速HIV感染者的衰老。

Recent studies make the case more directly. In May 2026 researchers writing in Nature Communications reported a post-hoc analysis of a trial in which people with HIV and lipohypertrophy, a condition in which excess fat builds up around the abdomen, took semaglutide (sold as Ozempic by Novo, a Danish firm). After about seven months, those on the drug showed signs of slower biological ageing, as measured by “epigenetic clocks”, tests that estimate biological rather than chronological age. The drug seems to work by reducing persistent inflammation, which accelerates ageing in people with HIV.

15年前,人们对长寿药物的浓厚兴趣最终不了了之。2026年9月发表的第二项研究在小鼠身上进行,走得更远。加州大学伯克利分校的研究人员为年长雌性小鼠注射司美格鲁肽,直至其生命结束。其中位寿命比注射安慰剂的小鼠长约12%。两项发现都是初步的,且均未表明GLP-1药物确实能延缓人类衰老。但它们值得后续研究。

A flurry of interest in longevity drugs came to nothing 15 years ago A second study, in mice, which was published in September 2026, goes further. Researchers at the University of California, Berkeley, injected older female mice with semaglutide for the rest of their lives. Their median lifespan was about 12% longer than that of mice on a placebo. Both findings are preliminary, and neither shows that GLP-1 drugs actually slow ageing in humans. But they warrant follow-up studies.

一些公司从一开始就把衰老生物学纳入药物研发。利用人工智能开发药物的香港上市初创公司英矽智能正在测试一种治疗特发性肺纤维化的药物,这种疾病会使肺部形成瘢痕。该公司表示,这款药物可能也对衰老起作用。在一项早期试验对42名患者进行的分析中,六种“蛋白质组时钟”(通过循环蛋白质估算生物学年龄)显示,治疗12周后,接受治疗患者的生物学年龄更低。更大规模的试验将于2027年进行。

Some are building the biology of ageing into drug discovery from the start. Insilico Medicine, a Hong Kong-listed startup that uses AI to develop drugs, is testing a drug for idiopathic pulmonary fibrosis, a disease that scars the lungs. The firm says the drug may also act on ageing. In an analysis of 42 patients from an early-stage trial, six “proteomic clocks”, which estimate biological age from circulating proteins, put treated patients at a lower biological age after 12 weeks. Larger trials will take place in 2027.

其他人正在探索一种被称为表观遗传重编程的方法,旨在逆转表观基因组的年龄相关变化。表观基因组是控制基因开启或关闭的DNA化学标记。这一理念现已进入人体试验阶段。硅谷初创公司NewLimit计划于2027年开始临床试验,测试一种旨在逆转肝脏细胞衰老的表观遗传重编程疗法。哈佛大学的David Sinclair共同创立的竞争对手初创公司Life Biosciences,已于6月为首位患者给药,开展一项安全性试验,测试一种对眼部细胞进行部分重编程的疗法。该公司正在针对青光眼和一种突发性视神经损伤测试该疗法。

Others are pursuing an approach called epigenetic reprogramming, which aims to reverse age-related changes to the epigenome, the chemical markers on DNA that control which genes switch on or off. The idea is now moving into human trials. NewLimit, a Silicon Valley startup, plans to begin clinical trials in 2027 of an epigenetic-reprogramming therapy intended to reverse cellular ageing in the liver. Life Biosciences, a rival startup co-founded by David Sinclair of Harvard University, dosed its first patient in June in a safety trial of a therapy that partly reprogrammes cells in the eye. It is testing its treatment against glaucoma and a sudden form of optic-nerve damage.

在长寿药物研究的一次热潮于15年前以失败告终后,投资者和药企长期回避该领域,认为其科学可信度极低。GLP-1类药物的成功帮助改变了这一判断,也颇为贴切地让该领域获得了新生。NewLimit于6月融资4.35亿美元。行业巨头礼来公司宣布与Insilico Medicine达成合作,交易金额高达27.5亿美元。另一巨头诺华公司则与专注于年龄相关疾病的初创公司BioAge Labs合作,交易金额高达5.5亿美元。

After a flurry of interest in longevity drugs came to nothing 15 years ago, investors and drugmakers had long shunned the field as having little scientific credibility. The success of GLP-1 drugs has helped change that calculation and, somewhat aptly, given the field a new lease of life. NewLimit raised $435m in funding in June. Eli Lilly, an industry giant, has announced a partnership with Insilico Medicine worth up to $2.75bn. Novartis, another giant, has teamed up with BioAge Labs, a startup focusing on age-related diseases, in a deal worth up to $550m.

药企追逐这一新市场还有另一个原因。数据供应商IQVIA估计,到2030年,年销售额达2300亿美元的品牌药将面临仿制药或生物类似药的竞争,因为专利即将到期。治疗衰老曾被视为边缘探索,如今很可能成为该行业替代这部分收入的最佳机会。■

Drugmakers have a further reason to pursue this new market. Iqvia, a data provider, estimates that branded drugs worth $230bn in annual sales will face competition from generic or biosimilar versions by 2030 as patents expire. Treating ageing, once dismissed as a fringe pursuit, may well be the industry’s best shot at replacing that revenue. ■

阅读媒体原文 ↗